1. FDA: Guidance for industry developing products for weight management. Available from:http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071612.pdf.
2. Ahima RS, Flier JS. Leptin. Annu Rev Physiol. 2000;62:413-37
3. Ahima RS, Flier JS. Leptin. Annu Rev Physiol. 2000;62:413-37
4. Morton GJ, Blevins JE, Williams DL, Niswender KD, Gelling RW, Rhodes CJ, Baskin DG, Schwartz MW. Leptin action in the forebrain regulates the hindbrain response to satiety signals. J Clin Invest. 2005 Mar;115(3):703-10.
5. Morton GJ, Matsen M, Figlewicz D, Schwartz MW. Leptin signaling in the ventral tegmental area enhances the satiety response to cholecystokinin. Diabetes. 2007;56:A403.
6. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Earley AR,Barnett AH, Prins JB, O'Rahilly S. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997 Jun 26;387(6636):903-8
7. Rosenbaum M, Goldsmith R, Bloomfield D, Magnano A, Weimer L, Heymsfield S, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest. 2005;115(12):3579-86
8. Rosenbaum M, Goldsmith R, Bloomfield D, Magnano A, Weimer L, Heymsfield S, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest. 2005;115(12):3579-86
9. Rosenbaum M, Murphy EM, Heymsfield SB, Matthews DE, Leibel RL. Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab. 2002;87:2391–2394. 
10. Kissileff HR, Thornton JC, Torres M, et al. Maintenance of reduced body weight in humans is associated with leptin-reversible changes in appetite-related ratings [abstract]; Presented at the Society for Neuroscience Annual Meeting; San Diego, California. 3–7 November 2007.
11. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999;282(16):1568-75
12. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 1999;283(5407):1544-8. 
13. Picardi PK, Calegari VC, Prada PO, Moraes JC, Araújo E, Marcondes MC, et al. Reduction of hypothalamic protein tyrosine phosphatase improves insulin and leptin resistance in diet-induced obese rats. Endocrinology. 2008;149(8):3870-80.
14. Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, Myers MG, Jr, Ozcan U. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metabolism. 2009;9:35–51
15. Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE, Anderson CM, Parkes DG, Baron AD. Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies. Proc. Natl. Acad. Sci. U. S. A. 2008;105:7257–7262
16. Amylin Pharmaceuticals, Inc. Available from: http://www.takeda.com/press/article_35851.html
17. Takeda Pharmaceutical Company Limited. Available from: http://www.takeda.com/press/article_42791.html
18. Fehm HL, Smolnik R, Kern W, McGregor GP, Bickel U, Born J. The melanocortin melanocyte-stimulating hormone adren-ocorticotropin(4-10) decreases body fat in humans. J Clin Endocrinol Metab. 2001;86(3):1144-8
19. Pissios P, Bradley RL, Maratos-Flier E. Expanding the scales: the multiple roles of MCH in regulating energy balance and other biological functions. Endocr Rev. 2006;27(6):606-20
20. Bristol-Myers Squibb metabolics clinical trial registry. Available from: http://ctr.bms.com/OneBmsCtd/InitTrialAction.do?linkname=Metabolics&type=pharma&sortby=default.
21. Launay JM, Herve P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet  L, Humbert M, Simonneau G and Maroteaux L (2002) Function of the serotonin  5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nature Medicine 8:1129-1135.
22. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun J-H,  Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC,  Robichaud AJ and Robertson DW (2000) ACCELERATED  COMMUNICATION: Possible Role of Valvular Serotonin 5-HT2B Receptors in  the Cardiopathy Associated with Fenfluramine. Mol Pharmacol 57:75-81.
23. Dunlop J, Sabb A and Mazandarani H (2005) WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,  10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1 hi]indole], a novel 5- hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J.  Pharmacol. Exp. Ther. 313:862-869.
24. Siuciak JA, Chapin DS, McCarthy SA, Guanowsky V, Brown J, Chiang P, Marala R,  Patterson T, Seymour PA, Swick A and Iredale PA (2007) CP-809,101, a JPET #179572  25  selective 5-HT2C agonist, shows activity in animal models of antipsychotic  activity. Neuropharmacology 52:279-290.
25. Ramamoorthy P, Beyer C, Brennan J, Dunlop J, Gove S, Grauer S, Harrison BL, Lin Q,  Malberg J, Marquis K, Mazandarani H, Piesla M, Pulicicchio C, RosenzweigLipson S, Sabb A-M, Schechter L, Stack G and J Z (2006) Discovery of SCA-136, a novel 5-HT2C agonist, for the treatment of schizophrenia. . 231st American Chemical Society National Meeting:MEDI-021.
26. Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, Whelan  K, Martin M, Morgan M, Chen W, Al-Shamma H, Smith B, Chalmers D and  Behan D (2008) Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C  Agonist: in Vitro and in Vivo Pharmacological Characterization. J Pharmacol  Exp Ther 325:577-587.
27. Arena Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results of               Novel Anti-Obesity Compound. Available from:
http:// www.invest.arenapharm.com/releasedetail.cfm?ReleaseID=320421
28. Complete Response Letter for Lorcaserin NDA. FDA Issues Complete                     Response Letter for Lorcaserin New Drug Application. Available from: http://www.drugs.com/nda/lorcaserin_101025.html.
29. TransTech Pharma obesity product pipeline. Available from: http://www.ttpharma.com/TherapeuticAreas/MetabolicDiseases/Obesity/TTP435/tabid/126/Default.aspx.
30. Kirkham TC, Tucci SA. Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets. 2006;5(3):272-92.         
31. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a metaanalysis of randomised trials. Lancet.2007;370(9600):1706-13.
32. Zarrindast MR, Hosseini-Nia T. Anorectic and behavioural effects of bupropion. Gen  Pharmacol. 1988;19(2):201-4.
33. Billes SK, Cowley MA. Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. Neuropsychopharmacology. 2007 Apr;32(4):822-34.
34.  Gadde KM, Yonish GM, Wagner HR 2nd, Foust MS, Allison DB. Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial. Int J Obes (Lond). 2006 Jul;30(7):1138-42.
35. Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, Gadde KM, Gupta AK, O'Neil P, Schumacher D, Smith D, Dunayevich E, Tollefson GD, Weber E, Cowley MA 2009 Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 17:30–39
36. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002;10(7):633-41.       
37. Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER, Leadbetter RA, Richard N, Haight B, Jamerson BD, Buaron KS, Metz A. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002 Oct;10(10):1049-56.
38. Gadde KM, Parker CB, Maner LG, Wagner HR 2nd, Logue EJ, Drezner MK, Krishnan KR. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001 Sep;9(9):544-51.
39. Cowley MA, Smart JL, Rubinstein M, Cerdán MG, Diano S, Horvath TL, Cone RD, Low MJ 2001 Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 411:480–484
40. Yeomans MR, Gray RW 2002 Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev 26:713–728
41. Atkinson RL, Berke LK, Drake CR, Bibbs ML, Williams FL, Kaiser DL 1985 Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther 38:419–422
42. Mitchell JE, Morley JE, Levine AS, Hatsukami D, Gannon M, Pfohl D 1987 High-dose naltrexone therapy and dietary counseling for obesity. Biol Psychiatry 22:35–42
43. Malcolm R, O'Neil PM, Sexauer JD, Riddle FE, Currey HS, Counts C 1985 A controlled trial of naltrexone in obese humans. Int J Obes 9:347–353
44. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010 Aug 21;376(9741):595-605.
45. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, Perri MG, Pi-Sunyer FX, Rock CL, Erickson JS, Maier HN, Kim DD, Dunayevich E. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011 Jan;19(1):110-20.
46. Okada M, Kaneko S, Hirano T, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995;22:193-205.
47. Okada M, Hirano T, Kawata Y, et al. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res. 1999;34:187-197.
48. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003 Apr 9;289(14):1820-5.
49. Lim J, Ko YH, Joe SH, Han C, Lee MS, Yang J. Zonisamide produces weight loss in psychotropic drug-treated psychiatric outpatients. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1918-21.
50.  McElroy SL, Kotwal R, Hudson JI, Nelson EB, Keck PE. Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. J Clin Psychiatry. 2004 Jan;65(1):50-6.
51. McElroy SL, Kotwal R, Guerdjikova AI, Welge JA, Nelson EB, Lake KA, D'Alessio DA, Keck PE, Hudson JI. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry. 2006 Dec;67(12):1897-906.
52. Orexigen Therapeutics, Inc. Press Release. Orexigen® Therapeutics Phase 2b Trial for Empatic™ Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients. Available from: http://ir.orexigen.Com/Phoenix.Zhtml?C=207034&P=Irol-Newsarticle&Id=1336796&Highlight
53. Gadde KM, Yonish GM, Foust MS, Wagner HR. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry. 2007 Aug;68(8):1226-9.
54. Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG. Cardiovascular effects of bupropion in depressed patients with heart disease. Am. J. Psychiatry 148(4), 512–516 (1991).
55. ZYBAN® (bupropion hydrochloride) sustained-release tablets. Available from: www.biopsychiatry.com/bupropion/bupropion-zyban.pdf
56. Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf. 30(7), 555–567 (2007).
57. Ohtahara S, Yamatogi Y. Safety of zonisamide therapy: prospective follow-up survey. Seizure 13(Suppl. 1), S50–S55; discussion S56 (2004).
58. Topiramate (Topamax®) tablets. Physicians' Desk Reference. Medical Economics Co., Inc: Montvale, NJ; 2002. pp 2590–2595.
59. Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther. 1997;19(6):1294-308.       
60. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH, for the US Topiramate Research Group. A 6-month randomized, placebo-controlled dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11: 722–733. 
61. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M; OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord. 2004 Nov;28(11):1399-410.
62. McElroy SL, Arnold LM, Shapira NA, Keck PE Jr, Rosenthal NR, Karim MR, Kamin M, Hudson JI. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003 Feb;160(2):255-61.
63. Hoopes SP, Reimherr FW, Hedges DW, Rosenthal NR, Kamin M, Karim R, Capece JA, Karvois D. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry. 2003 Nov;64(11):1335-41.
64. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Apr 16;377(9774):1341-52. Epub 2011 Apr 8. Erratum in: Lancet. 2011 Apr 30;377(9776):1494.
65. VIVUS: Qnexa meets primary endpoint by demonstrating superior weight loss over components and placebo in the 28-week equate study (OB-301). Available from: http://ir.vivus.com/releasedetail.cfm?releaseid=353965
66. VIVUS Inc. Press releases (2010). Available from: http://ir.vivus.com/releases.cfm?year=&releasestype=&pagenum=2
67. Vivus. FDA issues complete response letter to VIVUS regarding new drug application for QNEXA [press release]. October 28, 2010.
68. Broberger C, Landry M, Wong H, Walsh JN, Hökfelt T. Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin-and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology. 1997;66(6):393-408.
69. Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 2006;4(4):275-82. 
70. Sargent BJ, Moore NA. New central targets for the treatment of obesity. Br J Clin Pharmacol. 2009 Dec;68(6):852-60.
71. Gibbs, J., Young, R.C., Smith, G.P. 1973. Cholycystokinin elicits satiety in rats with open gastric fistulas. Nature. 245:323-325.
72. Moran, T.H., Katz, L.F., Plata-Salaman, C.R., Schwartz, G.J. 1998. Disordered food intake and obesity in rats lacking cholecystokinin A receptors. Am. J. Physiol. 274:R618-R625.
73. Kopin, A.S., et al. 1999. The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J. Clin. Invest. 103:383-391.
74. Moran, T.H., Kinzig, K.P. 2004. Gastrointestinal satiety signals. II. Cholecystokinin. Am. J. Physiol. Gastrointest. Liver Physiol. 286:G183-G188.
75. Zittel, T.T., et al. 1999. C-fos protein expression in the nucleus of the solitary tract correlates with cholecystokinin dose injected and food intake in rats. Brain Res. 846:1-11.
76. Smith, G.P., Jerome, C., Cushin, B.J., Eterno, R., Simansky, K.J. 1981. Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. Science. 213:1036-1037.
77. Moran, T.H., Baldessarini, A.R., Salorio, C.F., Lowery, T., Schwartz, G.J. 1997. Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. Am. J. Physiol. 272:R1245-R1251.
78. Joyner, K., Smith, G.P., Gibbs, J. 1993. Abdominal vagotomy decreases the satiating potency of CCK-8 in sham and real feeding. Am. J. Physiol. 264:R912-R916.
79. Schwartz, G.J., McHugh, P.R., Moran, T.H. 1993. Gastric loads and cholecystokinin synergistically stimulate rat gastric vagal afferents. Am. J. Physiol. 265:R872-R876.
80. Moran, T.H., McHugh, P.R. 1982. Cholecystokinin suppresses food intake by inhibiting gastric emptying. Am. J. Physiol. 242:R491-R497.
81. Kissileff, H.R., Carretta, J.C., Geliebter, A., Pi-Sunyer, F.X. 2003. Cholecystokinin and stomach distension combine to reduce food intake in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol.285:R992-R998.
82. M. O. Weickert, M. Mohlig, J. Spranger, C. Schofl, C. V. Loeffelholz, R. L. Riepl, B. Otto, and A. F. H. Pfeiffer. Effects of Euglycemic Hyperinsulinemia and Lipid Infusion on Circulating Cholecystokinin. J Clin Endocrinol Metab. 2008,93(6):2328–2333
83. Kissileff, H.R., Pi-Sunyer, F.X., Thornton, J., Smith, G.P. 1981. C-terminal octapeptide of cholecystokinin decreases food intake in man. Am. J. Clin. Nutr. 34:154-160.
84. Muurahainen, N., Kissileff, H.R., Derogatis, A.J., Pi-Sunyer, F.X. 1988. Effects of cholecystokinin-octapeptide (CCK-8) on food intake and gastric emptying in man. Physiol. Behav. 44:645-649.
85. Crawley, J.N., Beinfeld, M.C. 1983. Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature. 302:703-706.
86. Pi-Sunyer X, Kissileff HR, Thornton J, Smith GP. C-terminal octapeptide of cholecystokinin decreases food intake in obese men. Physiol Behav. 1982 Oct;29(4):627-30.
87. West, D.B., Fey, D., Woods, S.C. 1984. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am. J. Physiol. 246:R776-R787.
88.  Emma Janet Castillo,Silvia Delgado-Aros , Michael Camilleri,Duane Burton, Debra Stephens, Robin O'Connor-Semmes, Ann Walker, Anne Shachoy-Clark, and Alan R. Zinsmeister.  Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers. AJP - GI August 2004 vol. 287 no. 2 G363-G369
89. Schwartz, M.W., Woods, S.C., Porte, D., Seeley, R.J., Baskin, D.G. 2000. Central nervous system control of food intake. Nature. 404:661-671.
90. Morton, G.J., Cummings, D.E., Baskin, D.G., Barsh, G.S., Schwartz, M.W. 2006. Central nervous system control of food intake and body weight. Nature. 443:289-295.
91. Lee JY, Ye J, Gao Z, Youn HS, Lee WH, Zhao L, et al. Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem. 2003;278(39):37041-51
92. Verdich, C., et al. 2001. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J. Clin. Endocrinol. Metab. 86:4382-4389.
93. Gutzwiller, J.P., et al. 1999. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut. 44:81-86.
94. Naslund, E., et al. 1999. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int. J. Obes. Relat. Metab. Disord.23:304-311.
95. Toft-Nielsen, M.B., Madsbad, S., Holst, J.J. 1999. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 22:1137-1143.
96. Zander, M., Madsbad, S., Madsen, J.L., Holst, J.J. 2002. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 359:824-830.
97. Henry, R., et al. 2006. Exenatide maintained glycemic control with associated weight reduction over 2 years in patients with type 2 diabetes [abstract]. In66th Scientific Sessions of the American Diabetes Association. June 9–13, 2006. Washington, DC, USA. 485-P.
98. Abbott, C.R., et al. 2005. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res. 1044:127-131.
99. Talsania, T., Anini, Y., Siu, S., Drucker, D.J., Brubaker, P.L. 2005. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology. 146:3748-3756.
100. Baggio, L.L., Huang, Q., Brown, T.J., Drucker, D.J. 2004. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology. 127:546-558.
101. Drucker, D.J. 2006. The biology of incretin hormones. Cell Metab. 3:153-165.
102. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374:1606-1616.
103. Zealand Pharma product pipeline. Available from:                               www.zp.dk/%7BD566D263-F216–4A37-A38F-8C33A4ECC4E0%7D
104. Barnett AH. Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. Core Evid. 2011;6:67-79.
105. Pinelli NR, Hurren KM. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Pharmacother. 2011 Jul;45(7-8):850-60.
106. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ. An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future. Diabetes Obes Metab. 2011 May;13(5):394-407. doi: 10.1111/j.1463-1326.2011.01357.x.
107. Robert E Steinert, Birk Poller, M Cristina Castelli, Juergen Drewe, andChristoph Beglinger. Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. Am J Clin Nutr October 2010 vol. 92 no. 4 810-817
108. Beglinger C, Poller B, Arbit E, et al. Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects. Clin Pharmacol Ther 2008;84:468–74.
109. Steinert RE, Poller B, Castelli MC, et al. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. Clin Pharmacol Ther 2009;86(6):644–50.
110. Pironi, L., et al. 1993. Fat-induced ileal brake in humans: a dose-dependent phenomenon correlated to the plasma levels of peptide YY. Gastroenterology.105:733-739.
111. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003;349(10):941-8.         
112. Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C. Effect of peptide YY3-36 on food intake in humans. Gastroenterology. 2005 Nov;129(5):1430-6.
113. Field BC, Wren AM, Peters V, Baynes KC, Martin NM, Patterson M, Alsaraf S, Amber V, Wynne K, Ghatei MA, Bloom SR. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obesehumans. Diabetes. 2010 Jul;59(7):1635-9.
114. Gantz I, Erondu N, Mallick M, Musser B, Krishna R, Tanaka WK, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab. 2007;92(5):1754-7.         
115. Talsania, T., Anini, Y., Siu, S., Drucker, D.J., Brubaker, P.L. 2005. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology. 146:3748-3756.
116. Scott, V., Kimura, N., Stark, J.A., Luckman, S.M. 2005. Intravenous peptide YY3-36 and Y2 receptor antagonism in the rat: effects on feeding behaviour. J. Neuroendocrinol. 17:452-457.
117. Halatchev, I.G., Ellacott, K.L., Fan, W., Cone, R.D. 2004. Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology. 145:2585-2590.
118. Adams, S.H., Won, W.B., Schonhoff, S.E., Leiter, A.B., Paterniti, J.R. 2004. Effects of peptide YY[3-36] on short-term food intake in mice are not affected by prevailing plasma ghrelin levels. Endocrinology. 145:4967-4975.
119. Challis, B.G., et al. 2004. Mice lacking POMC are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). Proc. Natl. Acad. Sci. U. S. A. 101:4695-4700.
120. Pittner, R.A., et al. 2004. Effects of PYY[3-36] in rodent models of diabetes and obesity. Int. J. Obes. Relat. Metab. Disord. 28:963-971.
121. Chelikani, P.K., Haver, A.C., Reeve, J.R., Keire, D.A., Reidelberger, R.D. 2006. Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290:R298-R305.
122. Moran, T.H., et al. 2005. Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288:R384-R388.
123. Batterham, R.L., et al. 2002. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 418:650-654.
124. 7TM Pharma. 7TM Pharma's new first-in-class anti-obesity drug completes Phase I/II clinical studies. Press release [online] 2006.
125. Dakin, C.L., et al. 2001. Oxyntomodulin inhibits food intake in the rat. Endocrinology. 142:4244-4250.
126. Dakin, C.L., et al. 2004. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology. 145:2687-2695.
127. Baggio, L.L., Huang, Q., Brown, T.J., Drucker, D.J. 2004. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology. 127:546-558.
128. Yamamoto, H., et al. 2002. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Invest. 110:43-52.
129. Cohen, M.A., et al. 2003. Oxyntomodulin suppresses appetite and reduces food intake in humans. J. Clin. Endocrinol. Metab. 88:4696-4701.
130. Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes. 2005;54(8):2390-5
131. Wynne, K., et al. 2006. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int. J. Obes. (Lond.). 30:1729-1736.
132. Santoprete A, Capitò E, Carrington PE, Pocai A, Finotto M, Langella A, Ingallinella P, Zytko K, Bufali S, Cianetti S, Veneziano M, Bonelli F, Zhu L, Monteagudo E,Marsh DJ, Sinharoy R, Bianchi E, Pessi A. DPP-IV-resistant, long-acting oxyntomodulin derivatives. J Pept Sci. 2011 Apr;17(4):270-80.
133. Kerr BD, Flatt PR, Gault VA. (D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions. Biochem Pharmacol. 2010 Dec 1;80(11):1727-35.
134. Cummings, D.E., Foster-Schubert, K.E., Overduin, J. 2005. Ghrelin and energy balance: focus on current controversies. Curr. Drug Targets.6:153-169.
135. Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, Kangawa K, Nakazato M. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology. 2002 Oct;123(4):1120-8.
136. Wren, A.M., et al. 2001. Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. 86:5992-5995.
137. Zorrilla EP, Iwasaki S, Moss JA, Chang J, Otsuji J, Inoue K, Meijler MM, Janda KD.  Vaccination against weight gain. Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13226-31.
138. Moran TH, Dailey MJ. Minireview: Gut peptides: targets for antiobesity drug development? Endocrinology. 2009 Jun;150(6):2526-30.
139. Xin Z, Serby MD, Zhao H, Kosogof C, Szczepankiewicz BG, Liu M, Liu B, Hutchins CW, Sarris KA, Hoff ED, Falls HD, Lin CW, Ogiela CA, Collins CA,Brune ME, Bush EN, Droz BA, Fey TA, Knourek-Segel VE, Shapiro R, Jacobson PB, Beno DW, Turner TM, Sham HL, Liu G. Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists. J Med Chem. 2006 Jul 27;49(15):4459-69.
140. Yang J, Zhao T-J, Goldstein JL, Brown MS. Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides. Proceedings of the National Academy of Sciences.2008;105:10750–10755.
141. Okada, S., York, D.A., Bray, G.A., Mei, J., Erlanson-Albertsson, C. 1992. Differential inhibition of fat intake in two strains of rat by the peptide enterostatin. Am. J. Physiol. 262:R1111-R1116.
142. Kovacs, E.M., Lejeune, M.P., Westerterp-Plantenga, M.S. 2003. The effects of enterostatin intake on food intake and energy expenditure.Br. J. Nutr. 90:207-214.
143. Morton NM, Emilsson V, Liu YL, and Cawthorne MA. Leptin action in intestinal cells. J Biol Chem 273: 26194–26201, 1998.
144. Doi T, Liu M, Seeley RJ, Woods SC, and Tso P. Effect of leptin on intestinal apolipoprotein AIV in response to lipid feeding. Am J Physiol Regul Integr Comp Physiol 281: R753–R759, 2001.
145. Attia N, Touzani A, Lahrichi M, Balafrej A, Kabbaj O, and Girard-Globa A. Response of apolipoprotein AIV and lipoproteins to glycaemic control in young people with insulin-dependent diabetes mellitus. Diabet Med 14: 242–247, 1997.
146. Black DD and Ellinas H. Apolipoprotein synthesis in newborn piglet intestinal explants. Pediatr Res 32: 553–558, 1992.
147. Fujimoto K, Cardelli JA, and Tso P. Increased apolipoprotein A-IV in rat mesenteric lymph after lipid meal acts as a physiological signal for satiation. Am J Physiol Gastrointest Liver Physiol 262: G1002–G1006, 1992.
148. Fujimoto K, Machidori H, Iwakiri R, Yamamoto K, Fujisaki J, Sakata T, and Tso P. Effect of intravenous administration of apolipoprotein A-IV on patterns of feeding, drinking and ambulatory activity of rats. Brain Res 608: 233–237, 1993.
149. Katsuura, G., Asakawa, A., Inui, A. 2002. Roles of pancreatic polypeptide in regulation of food intake. Peptides. 23:323-329.
150. Asakawa A, Inui A, Ueno N, Fujimiya M, Fujino MA, Kasuga M. Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice. Peptides. 1999 Dec;20(12):1445-8.
151. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, Frost GS, Ghatei MA, Bloom SR. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab. 2003 Aug;88(8):3989-92.
152. Jesudason DR, Monteiro MP, McGowan BM, Neary NM, Park AJ, Philippou E, Small CJ, Frost GS, Ghatei MA, Bloom SR. Low-dose pancreatic polypeptide inhibits food intake in man. Br J Nutr. 2007 Mar;97(3):426-9.
153. Neary NM, McGowan BM, Monteiro MP, Jesudason DR, Ghatei MA, Bloom SR. No evidence of an additive inhibitory feeding effect following PP and PYY 3-36 administration. Int J Obes (Lond). 2008 Sep;32(9):1438-40.
154. Lutz, T.A., Althaus, J., Rossi, R., Scharrer, E. 1998. Anorectic effect of amylin is not transmitted by capsaicin-sensitive nerve fibers. Am. J. Physiol. 274:R1777-R1782.
155. Roth JD, Anderson, C 2006 Antiobesity effects of the β-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology 147:5855–5864
156. Rushing, P.A., Hagan, M.M., Seeley, R.J., Lutz, T.A., Woods, S.C. 2000. Amylin: a novel action in the brain to reduce body weight.Endocrinology. 141:850-853.
157. Lutz, T.A., Geary, N., Szabady, M.M., Del Prete, E., Scharrer, E. 1995. Amylin decreases meal size in rats. Physiol. Behav. 58:1197-1202.
158. Young AA 1997 Amylin’s physiology and its role in diabetes. Curr Opin Endocrinol Diab4:282–290
159. Young AA, Vine W, Gedulin BR, Pittner R, Janes S, Gaeta LSL, Percy A, Moore CX, Koda JE, Rink TJ, Beaumont K 1996 Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Dev Res 37:231–248
160. Hollander, P., et al. 2004. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes. Res.12:661-668.
161. Chapman I, Parker B, Doran S, Feinle-Bisset C, Wishart J, Strobel S, Wang Y, Burns C, Lush C, Weyer C, Horowitz M 2005 Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 48:838–848
162. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG 2003 Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 26:784–790
163. Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007;92(8):2977-83.         
164. Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE, Anderson CM, Parkes DG, Baron AD. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A. 2008 May 20;105(20):7257-62.
165. Trevaskis JL, Coffey T, Cole R, Lei C, Wittmer C, Walsh B, Weyer C, Koda J, Baron AD, Parkes DG, Roth JD. Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology. 2008 Nov;149(11):5679-87.
166. Roth JD, Coffey T, Jodka CM, Maier H, Athanacio JR, Mack CM, Weyer C, Parkes DG. Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity. Endocrinology. 2007 Dec;148(12):6054-61.
167. Aronne LJ, Halseth AE, Burns CM, Miller S, Shen LZ. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity (Silver Spring). 2010 Sep;18(9):1739-46.
168. Kopelman P, Bryson A, Hickling R, Rissanen A, Rossner S, Toubro S, Valensi P. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond). 2007 Mar;31(3):494-9.
169.  Bryson A, de la Motte S, Dunk C. Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers. Br J Clin Pharmacol. 2009 Mar;67(3):309-15.
170. Kopelman P, Groot Gde H, Rissanen A, Rossner S, Toubro S, Palmer R, Hallam R, Bryson A, Hickling RI. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring). 2010 Jan;18(1):108-15.
171. Scacchi, M., Pincelli, A. I., Cavagnini, F. (1999) Growth hormone in obesity.Int J Obes Relat Metab Disord. 23: 260–271. 
172. Shadid S, Jensen MD. Effects of growth hormone administration in human obesity. Obes Res. 2003 Feb;11(2):170-5.
173. The Phase 2B trial results for Metabolic's drug, AOD9604, do not support the commercial viability of the drug as a treatment for obesity. Development of the drug for this condition is terminated. Available from: http://www.metabolic.com.au/files/POQ26IMG5C/ASX_OPTIONSStudyResults_21Feb2007.pdf.
174. Mathvink, R.J. et al. Discovery of a potent, orally bioavailable β3 adrenergic receptor agonist,(R)-N-[4-[2-[[2-Hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(tri fluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide. Journal of Medicinal Chemistry 43, 3832-6 (2000).
175. Van Baak, M.A. et al. Acute effect of L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure in obese men. Clinical Pharmacology and Therapeutics  71, 272-9 (2002).
176. Larsen, T.M. et al. Effect of a 28-d treatment with L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure and body composition in obese men. American Journal of Clinical Nutrition 76, 780-8 (2002).
177. Bujalska IJ, Kumar S, Stewart PM. 1997 Does central obesity reflect “Cushing’s disease of the omentum?” Lancet. 349:1210–1213.
178. Walker, B.R., Connacher, A.A., Lindsay, R.M., Webb, D.J. & Edwards, C.R.W. Carbenoxolone increases hepatic insulin sensitivity in man: A novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. Journal of Clinical Endocrinology and Metabolism  80, 3155-9 (1995).
179. Sandeep, T.C., Andrew, R., Homer, N.Z.M., Andrews, R.C., Smith, K. & Walker, B.R. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11β-hydroxysteroid dehydrogenase type 1 Inhibitor carbenoxolone. Diabetes  54, 872-9 (2005).
180. Liu J, Wang L, Zhang A, Di W, Zhang X, Wu L, Yu J, Zha J, Lv S, Cheng P, Hu M, Li Y, Qi H, Ding G, Zhong Y. Adipose tissue-targeted 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-induced obesity. Endocr J. 2011;58(3):199-209.
181. Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, Folkman MJ. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10730-5.
182. Kim YM, An JJ, Jin YJ, Rhee Y, Cha BS, Lee HC, Lim SK. Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732. J Mol Endocrinol. 2007 Apr;38(4):455-65.
183.  AngioLab’s candidates. Available from: http://angiolab.co.kr/
184. Koubova J, Guarente L. How does calorie restriction work? Genes Dev. 2003 Feb 1;17(3):313-21.
185. Blüher M, Kahn BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science. 2003 Jan 24;299(5606):572-4.
186. Frédéric Picard, Martin Kurtev, Namjin Chung, Acharawan Topark-Ngarm, Thanaset Senawong, Rita Machado de Oliveira, Mark Leid, Michael W. McBurney, and Leonard Guarente. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ. Nature. 2004 June 17; 429(6993): 771.
187. Lagouge, M. et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1[alpha]. Cell  127, 1109-22 (2006).
188. Feige, J.N. et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metabolism  8, 347-58 (2008).
189. Sirtris pipeline. Available from: http://www.sirtrispharma.com/pipeline.html
190. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J. Clin. Endocrinol. Metab. 89(6), 2608–2615 (2004).
191. Cummings DE, Shannon MH. Roles for ghrelin in the regulation of appetite and body weight. Arch. Surg. 138(4), 389–396 (2003).
192. Vincent RP, Le Roux CW. The satiety hormone peptide YY as a regulator of appetite. J. Clin. Pathol. 61(5), 548–552 (2008).
193. Batterham RL, Cohen MA, Ellis SM et al. Inhibition of food intake in obese subjects by peptide YY3–36. N. Engl. J. Med. 349(10), 941–948 (2003).
194. Le Roux CW, Welbourn R, Werling M et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann. Surg. 246(5), 780–785 (2007).